Administration, Oral
"Administration, Oral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The giving of drugs, chemicals, or other substances by mouth.
Descriptor ID |
D000284
|
MeSH Number(s) |
E02.319.267.100
|
Concept/Terms |
Administration, Oral- Administration, Oral
- Drug Administration, Oral
- Oral Drug Administration
- Oral Administration
- Administrations, Oral
- Oral Administrations
- Administration, Oral Drug
- Administrations, Oral Drug
- Drug Administrations, Oral
- Oral Drug Administrations
|
Below are MeSH descriptors whose meaning is more general than "Administration, Oral".
Below are MeSH descriptors whose meaning is more specific than "Administration, Oral".
This graph shows the total number of publications written about "Administration, Oral" by people in this website by year, and whether "Administration, Oral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 8 | 8 | 1996 | 0 | 5 | 5 | 1997 | 0 | 7 | 7 | 1998 | 0 | 10 | 10 | 1999 | 0 | 3 | 3 | 2000 | 0 | 7 | 7 | 2001 | 0 | 6 | 6 | 2002 | 0 | 12 | 12 | 2003 | 0 | 8 | 8 | 2004 | 0 | 24 | 24 | 2005 | 0 | 15 | 15 | 2006 | 0 | 9 | 9 | 2007 | 0 | 22 | 22 | 2008 | 0 | 18 | 18 | 2009 | 0 | 13 | 13 | 2010 | 0 | 27 | 27 | 2011 | 0 | 19 | 19 | 2012 | 0 | 30 | 30 | 2013 | 0 | 19 | 19 | 2014 | 0 | 30 | 30 | 2015 | 0 | 23 | 23 | 2016 | 0 | 34 | 34 | 2017 | 0 | 31 | 31 | 2018 | 0 | 44 | 44 | 2019 | 1 | 37 | 38 | 2020 | 0 | 31 | 31 | 2021 | 0 | 23 | 23 | 2022 | 0 | 8 | 8 | 2023 | 0 | 9 | 9 | 2024 | 0 | 19 | 19 | 2025 | 0 | 9 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Administration, Oral" by people in Profiles.
-
Craig A, Shihadeh KC, Knepper BC, Miller W, Young HL, Aragon D, Jenkins TC. Antibiotic adherence and treatment completion associated with partial oral therapy versus all intravenous therapy in patients with serious Staphylococcus aureus infections. BMC Infect Dis. 2025 May 17; 25(1):714.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
-
Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24; 392(16):1569-1581.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. J Int AIDS Soc. 2025 Apr; 28(4):e26445.
-
Loupy KM, Dawud LM, Zambrano CA, Lee T, Heinze JD, Elsayed AI, Hassell JE, D'Angelo HM, Frank MG, Maier SF, Brenner LA, Lowry CA. Effects of Oral Administration of the Probiotic Lactobacillus rhamnosus GG on the Proteomic Profiles of Cerebrospinal Fluid and Immunoregulatory Signaling in the Hippocampus of Adult Male Rats. Neuroimmunomodulation. 2025; 32(1):94-109.
-
Noguchi LM, Owor M, Mgodi NM, Gati Mirembe B, Dadabhai S, Horne E, Gundacker H, Richardson BA, Bunge K, Scheckter R, Song M, Marzinke MA, Anderson PL, Livant E, Jacobson C, Piper JM, Chakhtoura N, Hillier SL, Balkus JE. Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial. Lancet HIV. 2025 Mar; 12(3):e180-e190.
-
Mourad A, Nwafo N, Skalla L, Holland TL, Jenkins TC. Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin Infect Dis. 2025 02 05; 80(1):29-36.
-
Ard JD, Ryan DH, O'Neil PM, Kushner RF, Wyatt HR, Bays HE, Greenway FL, Jakicic JM, Leonard S, Kenan Y, Ganon-Elazar E, Wadden TA. Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study. Obesity (Silver Spring). 2025 Mar; 33(3):500-511.
-
O'Malley SS, Miranda R, Book SW, Chun TH, Liss T, Malcolm RJ, Muvvala SB, Padovano HT, Schacht JP, Blackburn B, Diamond I, Ransom J, Ryan ML, Falk DE, Litten RZ. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol Alcohol. 2025 Jan 19; 60(2).
-
Lloyd M, Morton JI, Peters RL, Loke P, Ashley S, Shaker MS, Greenhawt M, Ademi Z, Tang MLK. Cost-Effectiveness of Oral Immunotherapy for Egg Allergy According to Age of Therapy Commencement. J Allergy Clin Immunol Pract. 2025 Mar; 13(3):619-629.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|